← Leaderboards
R M Goldberg
Mayo Clinic Coll Of Medicine, Rochester
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Alex A Adjei$13,436,633
- Neil E Kay$14,251,394
- Charles Erlichman$15,466,165
- Robert B. Jenkins$6,438,057
- Franklyn G Prendergast$4,072,258
Others in their field
Top investigators on “Drug Metabolism”
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$144,157,234
- Judith S. Currier · University Of California Los Angeles$139,585,289
- Randall J Bateman · Washington University$123,297,340
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Carol Nesel · Westat$116,355,411
Research focus
Drug MetabolismDrug Screening /EvaluationClinical ResearchHuman SubjectNeoplasm /Cancer ChemotherapyDosageClinical Trial Phase ILiver FunctionLiver MetabolismNeoplasm /CancerPharmacokineticsAntineoplasticsThymidylate SynthaseCombination ChemotherapyDrug Adverse EffectEnzyme InhibitorsHuman Therapy EvaluationIdoxuridineIrinotecan
Grant awards (6)
PHASE I TRIAL OF TOMUDEX AND IDURD IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2002 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR PATIENTS W HEPATIC$0
M01 · FY2002 · RR
PHASE I TRIAL OF TOMUDEX AND IDURD IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2001 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR PATIENTS W HEPATIC$0
M01 · FY2001 · RR
PHASE I TRIAL OF TOMUDEX AND IDURD IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2000 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR PATIENTS W HEPATIC$0
M01 · FY2000 · RR